Abstracts tagged "treatment"

Abstract Number: 439 • 2013 ACR/ARHP Annual Meeting
Tofacitinib, An Oral Janus Kinase Inhibitor: Analysis Of Gastrointestinal Adverse Events Across The Rheumatoid Arthritis Clinical Program
E. B. Lee¹, J. R. Curtis², R. Riese³, C. A. Connell³, R. Chew³, M.G. Boy³, E. Maller⁴, C. Su⁴ and L. Wang³, ¹Seoul National University, Seoul, South Korea, ²Rheumatology & Immunology, University of Alabama at Birmingham, Birmingham, AL, ³Pfizer Inc, Groton, CT, ⁴Pfizer Inc, Collegeville, PA
Background/Purpose: Tofacitinib is a novel, oral Janus kinase inhibitor being investigated as a targeted immunomodulator in rheumatoid arthritis (RA). This analysis aimed to describe and…
Abstract Number: 2112 • 2013 ACR/ARHP Annual Meeting
Hip and Knee Arthroplasty In Patients With Rheumatoid Arthritis: Results From The Australian Orthopaedic Association National Joint Replacement Registry: 2003 To 2011
Andrew Lim¹, Stephen Graves², Yen Liu², Lionel Schachna¹ and Russell R. Buchanan¹, ¹Rheumatology, Austin Health, Melbourne, Australia, ²Australian Orthopaedic Association National Joint Replacement Registry, Adelaide, Australia
Background/Purpose: Total Joint Replacement in rheumatoid arthritis (RA) patients is a marker of disease severity. Whilst the rate of total hip (THA) and total knee…
Abstract Number: 796 • 2013 ACR/ARHP Annual Meeting
Drug Exposure Limitations of Oral Methotrexate (MTX) At Doses >15mgs May be Overcome By Using a Subcutaneous MTX Auto-Injector in Patients With Rheumatoid Arthritis (RA)
Michael H. Schiff¹, Lee S. Simon², Bruce Freundlich³, Jonathan Jaffe⁴ and Kaushik J. Dave⁵, ¹Rheumatology Division, University of Colorado, Denver, CO, ²SDG LLC Consulting, West Newton, MA, ³University of Pennsylvania, Philadelphia, PA, ⁴Clinical Development, Antares Pharma Inc, Ewing, NJ, ⁵Product Development, Antares Pharma Inc, Ewing, NJ
Drug exposure limitations of oral methotrexate (MTX) at doses >15mgs may be overcome by using a subcutaneous MTX auto-injector in pts with rheumatoid arthritis (RA) Background/Purpose:…
Abstract Number: 1978 • 2013 ACR/ARHP Annual Meeting
The Effect Of Certolizumab On Lymphatic Volume and Flow In Rheumatoid Arthritis Patients With Acute Flare
Homaira Rahimi¹, Vaseem Chengazi², Gregory Dieudonne², Edward M. Schwarz³ and Christopher T. Ritchlin⁴, ¹Pediatrics, University of Rochester, Rochester, NY, ²Radiology, University of Rochester, Rochester, NY, ³Center for Musculoskeletal Research, University of Rochester, Rochester, NY, ⁴Allergy, Immunology and Rheumatology, University of Rochester, Rochester, NY
Background/Purpose: Episodic flare occurs in rheumatoid arthritis (RA) but the mechanisms of this process are not well understood. Our prior reports on MRI analysis of…
Abstract Number: 802 • 2013 ACR/ARHP Annual Meeting
Tofacitinib, An Oral Janus Kinase Inhibitor: Analysis Of Malignancies Across The Rheumatoid Arthritis Clinical Program
X. Mariette¹, J. R. Curtis², E. B. Lee³, B. Benda⁴, I. Kaplan⁵, K. Soma⁵, R. Chew⁵, J. Geier⁶, L. Wang⁷ and R. Riese⁵, ¹Paris-Sud University, Paris, France, ²Rheumatology & Immunology, University of Alabama at Birmingham, Birmingham, AL, ³Seoul National University, Seoul, South Korea, ⁴Pfizer Inc, Collegeville, PA, ⁵Pfizer Inc, Groton, CT, ⁶Pfizer Inc, New York, NY, ⁷Pfizer Worldwide R&D, Cambridge, MA
Background/Purpose: Tofacitinib is a novel, oral Janus kinase inhibitor for the treatment of rheumatoid arthritis (RA). This analysis extended the evaluation of malignancies that occurred…
Abstract Number: 1862 • 2013 ACR/ARHP Annual Meeting
Target-Directed Development Of a Proposed Biosimilar Etanercept, GP2015: Comparability Of In Vitro Target Binding and Pre-Clinical Efficacy and Pharmacokinetics
Antonio da Silva¹, Ulrich Kronthaler¹, Cornelius Fritsch², Johann Poetzl³, Adelheid Rohde⁴, Anastassia Papandrikopoulou⁵, Hans-Peter Hofmann⁶ and Jan Marinus Visser¹, ¹Preclinical Development, Sandoz Biopharmaceuticals / HEXAL AG, Holzkirchen, Germany, ²Bioassay Support Global Development, Novartis Pharma AG, Basel, Switzerland, ³Bioanalytics, Sandoz Biopharmaceuticals/Hexal AG, Oberhaching, Germany, ⁴Characterisation, Sandoz Biopharmaceuticals/Hexal AG, Kundl, Austria, ⁵Medical Communications, Sandoz Biopharmaceuticals / HEXAL AG, Holzkirchen, Germany, ⁶Pre-clinical, Sandoz Biopharmaceuticals/Hexal AG, Holzkirchen, Germany
Background/Purpose: Biosimilars are copy versions of existing biologic medicines that have lost patent exclusivity and are approved via stringent regulatory pathways. Biosimilars are designed to…
Abstract Number: 463 • 2013 ACR/ARHP Annual Meeting
An Indirect Comparisons Analysis Between Biologic Disease Modifiers in The Treatment Of Rheumatoid Arthritis To Evaluate For Efficacy and Safety
Aaron C. Garza Romero¹, Elie Donath¹, Hernan Osorno¹ and Suresh Kumar², ¹Internal Medicine, University of Miami Miller School of Medicine Palm Beach Regional Campus, Atlantis, FL, ²Rheumatology, University of Miami Miller School of Medicine Palm Beach Regional Campus, Atlantis, FL
Background/Purpose: There are primarily six groups of biologic disease modifiers (BDM) for treatment of rheumatoid arthritis (RA): tumor necrosis factor inhibitors (infliximab (IFX), etanercept (ETN),…
Abstract Number: 2802 • 2013 ACR/ARHP Annual Meeting
A Treat-To-Target Strategy With Methotrexate and Intra-Articular Triamcinolone With Or Without Added Adalimumab Reduces Synovitis, Osteitis and Tenosynovitis and Halts Structural Damage Progression In Early Rheumatoid Arthritis: The Opera Magnetic Resonance Imaging Sub-Study
Mette Bjørndal Axelsen^1,2, Iris Eshed³, Kim Hørslev-Petersen⁴, Kristian Steengaard-Petersen⁵, Merete L. Hetland⁶, Jakob M. Møller⁷, Peter Junker⁸, Jan Pødenphant⁹, Torkell Ellingsen¹⁰, Palle Ahlquist¹¹, Hanne M. Lindegaard¹², Asta Linauskas¹³, Annette Schlemmer¹⁴, Mette Yde Dam¹⁵, Ib Hansen¹⁶, Hans Chr Horn¹⁷, Christian G. Ammitzbøll¹⁸, Anette Jørgensen¹⁹, Sophine B. Krintel²⁰, Johnny Raun²¹, Julia S. Johansen²², Niels Steen Krogh²³ and Mikkel Østergaard⁶, ¹Copenhagen Center for Arthritis Research, Center for Rheumatology and Spine Diseases, Copenhagen University Hospital at Glostrup, Copenhagen, Denmark, ²Faculty of Health Sciences, Clinical Department of Orthopedics and Internal Medicine, Copenhagen University, Copenhagen, Denmark, ³Department of Radiology, Sheba Medical Center, Tel Hashomer, Israel, ⁴King Christian 10th Hospital for Rheumatic Diseases, South Jutland Hospital, Graasteen, Denmark, ⁵Department of Rheumatology, Aarhus University Hospital, Aarhus, Denmark, ⁶Copenhagen University Hospital Glostrup, Copenhagen, Denmark, ⁷Department of Radiology, Copenhagen University Hospital at Herlev, Copenhagen, Denmark, ⁸Odense University Hospital, Odense, Denmark, ⁹Copenhagen University at Gentofte, Hellerup, Denmark, ¹⁰Department of Internal Medicine, Diagnostic Centre Region Hospital Silkeborg Denmark, 8600 Silkeborg, Denmark, ¹¹Department of Internal Medicine, Vejle Regional Hospital, Vejle, Denmark, ¹²Department of Rheumatology, Odense University Hospital, Odense, Denmark, ¹³Vendsyssel Hospital, Hjørring, Denmark, ¹⁴Department of Rheumatology, Aalborg University Hospital, Aalborg, Denmark, ¹⁵Diagnostic Centre, Silkeborg Regional Hospital, Silkeborg, Denmark, ¹⁶Rheumatology, Department of Rheumatology, Aarhus University Hospital, Aarhus, Denmark, ¹⁷Internal Medicine/Rheumatology, Odense University Hospital, Odense, Denmark, ¹⁸Arhus University Hospital, Aarhus, Denmark, ¹⁹Rheumatology, Arhus University Hospital, Aarhus, Denmark, ²⁰Copenhagen Center for Arthritis Research, Center for Rheumatology and Spine Diseases, Copenhagen University Hospital at Glostrup, Glostrup, Denmark, ²¹University of Southern Denmark, Graasten, Denmark, ²²Department of Internal Medicine and Oncology, Herlev Hospital, Herlev, Denmark, ²³ZiteLab ApS, Copenhagen, Denmark
Background/Purpose: The aim was to investigate if a treat-to-target strategy with methotrexate and intra-articular glucocorticoid suppressed synovitis and osteitis, and halted structural damage progression in…
Abstract Number: 1865 • 2013 ACR/ARHP Annual Meeting
Complement Activation and Anaphylatoxin Generation In Response To Staphylococcal Protein A Exposure: Ex Vivo and In Vivo Human Studies
Edward Bernton¹, Antonio Polley², Susan Zondlo², Lynne Mitchell³ and Dennis Hourcade³, ¹Protalex Inc., Summit, NJ, ²QPS Holdings LLC, Newark, DE, ³Division of Rheumatology, Washington University School of Medicine, St. Louis, MO
Background/Purpose: PRTX-100, a highly-purified GMP staphylococcal protein A (SpA), is currently in clinical trials treating patients with active rheumatoid arthritis (RA). It has been reported…
Abstract Number: 465 • 2013 ACR/ARHP Annual Meeting
Higher Titer Of Anti-Citrullinated Protein Antibodies In Biologic-Naïve Rheumatoid Arthritis Patients Are Candidate Biomarkers To Predict Sensitivity Leading To Clinical Remission With Abatacept; Data From The Abroad Study
Takao Fujii¹, Masahiro Sekiguchi², Kiyoshi Matsui², Masayasu Kitano², Motomu Hashimoto³, Koichiro Ohmura⁴, Aihiro Yamamoto⁵, Hideko Nakahara⁶, Keiji Maeda⁷, Akira Yokota⁸, Kenji Miki⁹, Naoki Shimmyo¹⁰, Takanori Kuroiwa¹¹, Kosaku Murakami¹², Yoshio Ozaki¹³, Kenshi Higami¹⁴, Ichiro Yoshii¹⁵, Yuji Nozaki¹⁶, Takashi Ikawa¹⁷, Satoshi Morita¹⁸, Yutaka Kawahito⁵, Norihiro Nishimoto¹⁹, Tsuneyo Mimori⁴ and Hajime Sano², ¹Department of the Control for Rheumatic Diseases, Graduate School of Medicine, Kyoto University, Kyoto, Japan, ²Division of Rheumatology, Department of Internal Medicine, Hyogo College of Medicine, Nishinomiya-city, Japan, ³The Control for Rheumatic Diseases, Graduate School of Medicine, Kyoto University, Kyoto, Japan, ⁴Department of Rheumatology and Clinical Immunology, Graduate School of Medicine, Kyoto University, Kyoto, Japan, ⁵Department of Inflammation and Immunology, Graduate School of Medical Science, Kyoto Prefectural University of Medicine, Kyoto, Japan, ⁶Division of Allergy, Rheumatology and Connective Tissue Diseases, Department of Internal Medicine, NTT West Osaka Hospital, Osaka, Japan, ⁷Allergy, Rheumatology and Connective Tissue Diseases, Department of Internal Medicine, NTT West Osaka Hospital, Osaka, Japan, ⁸Yokota Clinic for Rheumatology, Osaka, Japan, ⁹Department of Orthopaedic Surgery, Amagasaki Central Hospital, Amagasaki, Japan, ¹⁰Kashiba Asahigaoka Hospital, Kashiba, Japan, ¹¹Department of Rheumatology, Yukioka Hospital, Osaka, Japan, ¹²Dept of Rheumatology and Clinical Immunology, Graduate School of Medicine, Kyoto University, Kyoto, Japan, ¹³Kansai Medical University Hirakata Hospital, Hirakata, Japan, ¹⁴Department of Rheumatology, Higami Hospital, Nara, Japan, ¹⁵Department of Orthopaedic Surgery, Yoshii Hospital, Shimanto, Japan, ¹⁶Kinki University Faculty of Medicine, Sayama, Japan, ¹⁷Osaka Rehabilitation Hospital, Hannan, Japan, ¹⁸Graduate School of Medicine & Medical Center, Department of Biostatistics and Epidemiology, Yokohama City University, Kanagawa, Japan, ¹⁹Osaka Rheumatology Clinic, Osaka, Japan
Background/Purpose: Biomarkers to predict each rheumatoid arthritis (RA) patient’s sensitivity for biologic disease modifying anti-rheumatic diseases, especially for the only T cell modulator abatacept (ABT),…
Abstract Number: 2641 • 2013 ACR/ARHP Annual Meeting
Earlier Admission To Specialized Care, Intensified Treatment and Improved Outcome In Patients With Autoimmune Connective Tissue Disorders and Vasculitides In Germany 2011 Compared To 1995
Dörte Huscher¹, Katinka Albrecht², Katja Thiele², Sascha Bischoff², Jutta G. Richter³, Ina Kötter⁴, Wolfgang Ochs⁵ and Angela Zink¹, ¹German Rheumatism Research Centre and Charité University Medicine, Berlin, Germany, ²German Rheumatism Research Centre, Berlin, Germany, ³Department of Rheumatology, Heinrich-Heine-University Duesseldorf, Duesseldorf, Germany, ⁴ZIRS, Centre for Interdisciplinary Rheumatology Stuttgart, Stuttgart, Germany, ⁵Rheumatologist in private practice, Bayreuth, Germany
Background/Purpose: Compared to rheumatoid arthritis and other arthritis-associated rheumatic diseases, autoimmune connective tissue disorders and vasculitides are still in the early stages of biological therapies.…
Abstract Number: 1792 • 2013 ACR/ARHP Annual Meeting
Inhibition Of Chemokine Receptors CCR1 and CCR6 As Promising Therapies For Autoimmune Diseases Such As Rheumatoid Arthritis and Psoriasis
Daniel Dairaghi¹, Penglie Zhang², Manmohan Leleti², Robert Berahovich³, Karen Ebsworth³, Linda Ertl³, Shichang Miao⁴, Zhenhua Miao³, Lisa Seitz³, Joanne Tan³, Matthew Walters³, Yu Wang³, Jay Powers⁵, Thomas J. Schall⁶ and Juan C. Jaen⁷, ¹Biology, ChemoCentryx, Inc., Mountain View, CA, ²Chemistry, ChemoCentryx, Mountain View, CA, ³Biology, ChemoCentryx, Mountain View, CA, ⁴Pharmacokinetics, ChemoCentryx, Inc., Mountain View, CA, ⁵ChemoCentryx, Mountain View, CA, ⁶ChemoCentryx, Inc., Mountain View, CA, ⁷Discovery and Preclinical Development, ChemoCentryx, Inc., Mountain View, CA
Background/Purpose: Chemokines are key regulators of leukocyte activation and recruitment to sites of inflammation. Of particular relevance in rheumatoid arthritis (RA), the chemokine receptors CCR1…
Abstract Number: 469 • 2013 ACR/ARHP Annual Meeting
Anti-TNF Therapy Induces Positive Changes In The Lipoprotein Profile Of RA Patientes. Results Of a Prospective Study
Jaime Calvo-Alén¹, Carmela Baamonde², Ignacio Villa¹, Víctor Martínez-Taboada³, Mario Agudo⁴ and Juan Gómez-Gerique⁵, ¹Rheumatology, Hospital Universitario Sierrallana, Torrelavega, Spain, ²Biochemistry, Hospital Universitario Sierrallana, Torrelavega, Spain, ³Rheumatology, Hospital Universitario Marqués de Valdecilla, Santander, Spain, ⁴Rheumatology, Hospital Universitario Marqués de Valdecilla. IFIMAV, Santander, Spain, ⁵Biochemistry, Hospital Universitario Marqués de Valdecilla. IDIVAL. Santander. Spain, Santander, Spain
Background/Purpose: Anti-TNF therapy induces elevations in total cholesterol levels although does not seem to modify the atherogenic index. Otherwise, it appears to have a cardiovascular…
Abstract Number: 2381 • 2013 ACR/ARHP Annual Meeting
The JAK1-Selective Inhibitor GLPG0634 Is Safe and Rapidly Reduces Disease Activity In Patients With Moderate To Severe Rheumatoid Arthritis; Results Of a 4-Week Dose Ranging Study
Chantal Tasset, Pille Harrison, Annegret Van der Aa, Luc Meuleners, Frédéric Vanhoutte and Gerben van 't Klooster, Galapagos NV, Mechelen, Belgium
Background/Purpose: GLPG0634 is an oral, selective inhibitor of Janus kinase 1 (JAK1). JAKs signal for cytokines and growth factors, including those involved in rheumatoid arthritis…
Abstract Number: 1793 • 2013 ACR/ARHP Annual Meeting
Oskira-1: A Phase III, Multicenter, Randomized, Double-Blind, Placebo-Controlled Parallel-Group Study Of 2 Dosing Regimens Of Fostamatinib In Rheumatoid Arthritis Patients With An Inadequate Response To Methotrexate
Michael Weinblatt¹, Mark C. Genovese², Meilien Ho³, Sally Hollis³, Krystyna Rosiak-Jedrychowicz⁴, Arthur Kavanaugh⁵, David Millson³, Gustavo Leon⁶, Millie Wang³ and Désiréé van der Heijde⁷, ¹Division of Rheumatology, Brigham & Women's Hospital, Boston, MA, ²Division of Immunology and Rheumatology, Stanford University, Palo Alto, CA, ³AstraZeneca R&D Alderley Park, Macclesfield, United Kingdom, ⁴Przychodnia Neuromedyka, Zyrardów, Poland, ⁵University of California, San Diego, La Jolla, CA, ⁶Instituto de Ginecología y Reproducción-Cirugía Mínimamente Invasiva, Surco, Peru, ⁷Department of Rheumatology, Leiden University Medical Center, Leiden, Netherlands
Background/Purpose: Fostamatinib (Fosta) is an oral SYK inhibitor. This 52-wk study (NCT01197521) compared Fosta vs placebo (PBO) + methotrexate (MTX) in patients (pts) with active…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].